Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1

NCT06358950 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT06358950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06358950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1
Lead sponsor
Alkermes, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 24, 2024
Completion date
July 31, 2025
Enrollment
92 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

narcolepsy type 1